ERBB2 and neoplasm: The reduced Src activation indicated by low Tyr416 phosphorylation levels in the bitransgenic tumours is corroborated by the reduced phosphorylation of ErbB2 at Tyr877 (Figure 3a), which is mediated by Src [24,25].